Analysts Offer Insights on Healthcare Companies: ADMA Biologics (NASDAQ: ADMA), Sarepta Therapeutics (NASDAQ: SRPT) and Clovis Oncology (NASDAQ: CLVS)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ADMA Biologics (ADMAResearch Report), Sarepta Therapeutics (SRPTResearch Report) and Clovis Oncology (CLVSResearch Report) with bullish sentiments.

ADMA Biologics (ADMA)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on ADMA Biologics, with a price target of $12.00. The company’s shares closed last Monday at $4.52.

According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -21.4% and a 25.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Hancock Jaffe Laboratories, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

Currently, the analyst consensus on ADMA Biologics is a Moderate Buy with an average price target of $9.67, which is a 91.9% upside from current levels. In a report issued on October 23, H.C. Wainwright also reiterated a Buy rating on the stock with a $13.00 price target.

See today’s analyst top recommended stocks >>

Sarepta Therapeutics (SRPT)

In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Sarepta Therapeutics, with a price target of $160.00. The company’s shares closed last Monday at $93.38.

According to TipRanks.com, Chattopadhyay is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -9.5% and a 34.7% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences, and Audentes Therapeutics.

Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $191.94, a 105.9% upside from current levels. In a report issued on November 1, Guggenheim also initiated coverage with a Buy rating on the stock with a $183.00 price target.

Clovis Oncology (CLVS)

H.C. Wainwright analyst Edward White reiterated a Buy rating on Clovis Oncology today and set a price target of $36.00. The company’s shares closed last Monday at $4.32, close to its 52-week low of $2.93.

According to TipRanks.com, White is a 5-star analyst with an average return of 14.3% and a 49.0% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Clovis Oncology with a $12.65 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.